Evidence map›Paper›PMID 41789104›Full record

ReviewFrontiers in immunology2026

Combining advanced radiotherapy techniques and immunotherapy: immunomodulatory mechanisms and clinical prospects.

Linsen Zhou, Qianyi Liu, Yongze He, Ying Tang, Shuotong Liu, Xiaobin Wang, Shiyan Shen, Jialin Ji, Zhen Liu, Xianhu Zeng and 1 more

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Linsen ZhouDepartment of Radiotherapy Physics & Technology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Qianyi LiuDepartment of Radiotherapy Physics & Technology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yongze HeDepartment of Radiotherapy Physics & Technology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Ying TangWest China School of Medicine, Sichuan University, Chengdu, Sichuan, China.
Shuotong LiuWest China School of Medicine, Sichuan University, Chengdu, Sichuan, China.
Xiaobin WangDepartment of Radiotherapy Physics & Technology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Shiyan ShenDepartment of Radiotherapy Physics & Technology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Jialin JiDepartment of Radiotherapy Physics & Technology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Zhen LiuDepartment of Radiotherapy Physics & Technology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Xianhu ZengDepartment of Radiotherapy Physics & Technology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Jiangping LiDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review systematically explores the mechanisms and clinical prospects of combining advanced radiotherapy techniques-including stereotactic body radiotherapy, FLASH radiotherapy, proton therapy, carbon ion radiotherapy, and spatially fractionated radiotherapy-with immunotherapy. It elucidates how radiotherapy activates systemic antitumor immunity by inducing immunogenic cell death, activating the cGAS-STING pathway, upregulating MHC-I expression, and remodeling the tumor microenvironment. These mechanisms synergize with immune checkpoint inhibitors to enhance both local and systemic tumor control, including the abscopal effect. Compared with conventional radiotherapy, these advanced techniques leverage precise dose distributions, ultra-high dose rates, or the Bragg Peak physical properties to better protect normal tissues, mitigate radiation-induced lymphopenia, and favorably modulate the tumor microenvironment. Although preclinical studies and emerging clinical trials support the feasibility and efficacy of such combinations, further large-scale, well-designed clinical trials are required to validate their optimal application strategies and long-term benefits.

Indexed as

ImmunomodulationImmunotherapyNeoplasmsAnimalsCombined Modality TherapyHumansImmune Checkpoint InhibitorsTumor MicroenvironmentImmune Checkpoint Inhibitorscarbon ion radiotherapyFLASH radiotherapyimmune checkpoint inhibitorsimmunotherapyproton therapySBRTSFRTtumor microenvironment

Identifiers

PMID41789104
PMCPMC12956806

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.